ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > CD52

CD52

概要

Name:CAMPATH-1 antigen
Target Synonym:Epididymis Secretory Sperm Binding Protein Li 171mP,CD52 Antigen (CAMPATH-1 Antigen),Epididymal Secretory Protein E5,He5,CDW52 Antigen (CAMPATH-1 Antigen),CD52 Antigen,HEL-S-171mP,EDDM5,CD52,CDw52,Cambridge pathology 1 antigen,Human epididymis-specific protein 5,CAMPATH-1 antigen,CD52 Molecule
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

CD2-H82E8-SPR
 CD52 SPR

Anti-Human CD52 MAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Biotinylated Human CD52, His,Avitag (Cat. No. CD2-H82E8) with an affinity constant of 71.8 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CD2-H82E8-BLI
 CD52 BLI

Loaded Biotinylated Human CD52, His,Avitag (Cat. No. CD2-H82E8) on SA Biosensor, can bind Anti-Human CD52 MAb (Human IgG1) with an affinity constant of 137 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

CDW52,HE5,CD52,CAMPATH-1 antigen

Background

CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene.It is widely expressed on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs).ligation of cell surface CD52 molecules may offer costimulatory signals for T-cell activation and proliferation.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Alemtuzumab LDP-03; GZ-402673 Approved Genzyme Corp, Bayer AG Campath, Lemtrada, MabCampath Japan Leukemia, Lymphocytic, Chronic, B-Cell Sanofi 2001-05-07 Myositis, Inclusion Body; Mycosis Fungoides; Leukemia, Lymphocytic, Chronic, B-Cell; Fallopian Tube Neoplasms; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Sezary Syndrome; Lymphoproliferative Disorders; Peritoneal Neoplasms; Pancytopenia; Diabetes Mellitus, Type 1; Rejection of organ transplantation; Multiple Sclerosis; Myelodysplastic Syndromes; Leukemia-Lymphoma, Adult T-Cell; Kidney Diseases; Graft vs Host Disease; Ovarian Neoplasms; Bone marrow transplant rejection; Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Multiple Sclerosis, Relapsing-Remitting; Rejection of renal transplantation; Leukemia Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Alemtuzumab biosimilar (Zhangjiang Biotechnology) Phase 2 Clinical Shanghai Zhangjiang Biotechnology Co Ltd Leukemia, Lymphocytic, Chronic, B-Cell Details
Alemtuzumab biosimilar(BioXpress) BX-1523; BXT-1523 Clinical Bioxpress Therapeutics Sa Multiple Sclerosis; Leukemia, B-Cell Details
Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology) Phase 1 Clinical Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd Leukemia, B-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic Details
ALLO-647 ALLO-647 Phase 2 Clinical Allogene Therapeutics Inc Lymphoma, B-Cell; Carcinoma, Renal Cell; Multiple Myeloma; Lymphoma, Follicular Details

This web search service is supported by Google Inc.

totopphone